GlassScriptPhysician profile
Mylene S Go
NPI 1992964696
$8,083.68
in general payments reported to CMS, 2019-2025
72 companies · $1,781 in 2025
The $1,781 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,204 · 2020: $181 · 2021: $304 · 2022: $972 · 2023: $1,423 · 2024: $1,219 · 2025: $1,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,422.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $651.80 | 2019-2024 | Opdivo, Krazati, Eliquis |
| Novartis Pharmaceuticals Corporation | $433.34 | 2019-2025 | |
| Janssen Biotech, INC. | $395.02 | 2019-2025 | Tecvayli, Darzalex, Carvykti |
| Pfizer INC. | $347.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $339.04 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $315.89 | 2019-2025 | Reblozyl |
| Genentech USA, INC. | $293.38 | 2019-2024 | Polivy, Lunsumio, Gazyva |
| Astrazeneca Pharmaceuticals LP | $282.37 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Eisai INC. | $253.68 | 2019-2024 | |
| Glaxosmithkline, LLC. | $225.31 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Lilly USA, LLC | $214.17 | 2019-2025 | Verzenio, Jaypirca |
| Abbvie INC. | $188.92 | 2021-2025 | |
| Incyte Corporation | $187.17 | 2019-2025 | Jakafi |
| Astellas Pharma US INC | $181.04 | 2019-2025 | Padcev |
| Exelixis INC. | $177.08 | 2019-2025 | Cabometyx |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $166.64 | 2020-2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $163.50 | 2019-2023 | |
| Immunocore Limited | $158.60 | 2024-2025 | Kimmtrak |
| Daiichi Sankyo INC. | $152.74 | 2024-2025 | Enhertu, Datroway |
| Ipsen Biopharmaceuticals, INC | $152.02 | 2019-2025 | Tazverik, Onivyde |
| Seagen INC. | $151.39 | 2019-2023 | Padcev, Tukysa |
| Gilead Sciences, INC. | $150.11 | 2019-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $141.47 | 2020-2025 | Xpovio |
| Tesaro, INC. | $140.77 | 2019 | |
| Puma Biotechnology, INC. | $126.50 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $107.97 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Kite Pharma, INC. | $102.80 | 2019-2025 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $100.51 | 2021-2025 | |
| Sobi, INC | $85.23 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.23 | 2019-2025 | Gilotrif |
| Janssen Pharmaceuticals, INC | $79.84 | 2019-2022 | |
| Amgen INC. | $79.29 | 2019-2023 | Xgeva, Nplate, Blincyto |
| Pharmacosmos Therapeutics INC. | $72.45 | 2023-2025 | Monoferric |
| Tempus Ai, INC | $68.70 | 2024-2025 | Xt Cdx |
| Morphosys, US INC. | $64.93 | 2022-2024 | Monjuvi |
| Stemline Therapeutics INC. | $62.52 | 2023-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $61.74 | 2022-2025 | |
| Tersera Therapeutics LLC | $61.53 | 2019-2025 | Zoladex, Xermelo |
| Invivyd INC | $61.36 | 2025 | Pemgarda |
| Beigene USA, INC. | $61.08 | 2021-2025 | Tevimbra |
| Regeneron Healthcare Solutions, INC. | $53.45 | 2019-2023 | Libtayo |
| Beone Medicines USA, INC. | $51.43 | 2025 | Brukinsa, Tevimbra |
| Jazz Pharmaceuticals INC. | $50.82 | 2025 | |
| Apellis Pharmaceuticals, INC. | $49.76 | 2023 | Empaveli |
| Geron Corporation | $49.75 | 2024-2025 | Rytelo |
| Genmab U.S., INC. | $47.40 | 2023-2024 | Tivdak, Epkinly |
| Servier Pharmaceuticals LLC | $46.61 | 2022-2024 | |
| Dova Pharmaceuticals | $40.22 | 2019 | |
| Spectrum Pharmaceuticals INC. | $39.99 | 2019-2023 | Rolvedon |
| Kyowa Kirin, INC. | $35.38 | 2019 | |
| Agios Pharmaceuticals, INC. | $35.37 | 2023-2024 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $35.05 | 2022-2023 | Alunbrig |
| Tolmar, INC. | $34.35 | 2023-2025 | Eligard, Rubraca |
| Array Biopharma INC | $32.51 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Acrotech Biopharma INC. | $31.96 | 2022-2025 | Ryzneuta |
| Emd Serono, INC. | $28.57 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $27.21 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.58 | 2024 | Ultomiris |
| G1 Therapeutics, INC. | $24.54 | 2023 | Cosela |
| Organon LLC | $24.03 | 2023-2025 | Ontruzant |
| Pharmaand Gmbh | $22.23 | 2025 | Rubraca |
| Springworks Therapeutics, INC. | $21.20 | 2025 | Gomekli |
| Deciphera Pharmaceuticals INC. | $18.41 | 2024 | Qinlock |
| Helsinn Therapeutics (U.S.), INC. | $15.98 | 2025 | Akynzeo |
| Amneal Pharmaceuticals LLC | $15.96 | 2025 | Alymsys |
| Mirati Therapeutics, INC. | $15.49 | 2023 | Krazati |
| Shield Therapeutics INC | $14.43 | 2025 | |
| Eusa Pharma (US) LLC | $14.38 | 2019 | |
| Sumitomo Pharma America, INC. | $13.50 | 2025 | Orgovyx |
| Fresenius Kabi USA, LLC | $13.32 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $12.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mylene Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.